When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and its Cardiovascular Safety.

Clicks: 387
ID: 34278
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 8 articles by views in arthritis & rheumatology (hoboken, nj)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In this issue of Arthritis and Rheumatology, Giles et al. report much awaited data from the ENTRACTE trial.(1) The United States Food and Drug Administration (FDA)-required this post-marketing randomized controlled trial (RCT) to study the risk of major adverse cardiovascular events (MACE) in patients with rheumatoid arthritis (RA) treated with monthly tocilizumab (TCZ) 8mg/kg intravenous infusions compared to the risk in those treated with weekly etanercept 50mg subcutaneous injections.(1) This article is protected by copyright. All rights reserved.
Reference Key
kim2019whenarthritis Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kim, Seoyoung C;Schneeweiss, Sebastian;
Journal arthritis & rheumatology (hoboken, nj)
Year 2019
DOI
10.1002/art.41092
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.